Table 1 Clinical characteristics of LVNC cohort.
From: Genetic architecture of left ventricular noncompaction in adults
All patients (n = 35) n, (%) | |
|---|---|
Female | 19 (54) |
Caucasian (European) ethnicity | 33 (94) |
Mean age at diagnosis (yrs) | 43.8 ± 12.3 |
NYHA class I | 29 (83) |
NYHA class II | 6 (17) |
LV systolic dysfunction (LVEF < 50%) | 12 (34) |
LVEF (%) | 53.1 ± 13.4 |
Hypertension | 7 (20) |
Presentation | |
Symptomatic (including palpitations, exertional dyspnoea, syncope and atrial fibrillation) | 26 (74) |
Incidental | 9 (26) |
Familial disease | 14 (40) |
Left ventricular non-compaction | 4 (11) |
Valvular disease | 2 (6) |
Septal defect | 2 (6) |
Hypertrophy | 2 (6) |
Dilated cardiomyopathy | 3 (9) |
Polycystic kidney disease | 2 (6) |
Holt-Oram syndrome | 2 (6) |
Muscle weakness | 1 (3) |
Sudden cardiac death | 1 (3) |
Structural features | |
Left atrial dilation | 19 (54) |
Left ventricle dilation | 10 (29) |
Prominent RV trabeculation | 13 (37) |
LVEDV (Indexed) | 90.63 ± 20.88 |
LVESV (Indexed) | 40.33 ± 21.21 |
RVEDV (Indexed) | 89.77 ± 16.10 |
RVESV (Indexed) | 39.18 ± 12.64 |
Resting and ambulatory ECG findings | |
Non-sustained ventricular tachycardia | 7 (20) |
Atrial fibrillation | 12 (34) |
Left bundle branch block | 6 (17) |
Right bundle branch block | 5 (14) |
Surgical/medical interventions | |
Aspirin | 18 (51) |
Pacemaker | 2 (6) |
Implantable cardioverter defibrillator | 9 (26) |
